Month: February 2026

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile –...

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing...

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the...

GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options

Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb reviews often evaluate when comparing...

error: Content is protected !!